PTCT · CIK 0001070081
What PTC Therapeutics, Inc. told the SEC could break it.
PTC's supply chain is thin and outsourced: it relies on single-source production for some raw materials behind Translarna and vatiquinone (and Emflaza), and depends on third-party manufacturers for the active ingredient and the manufacturing, packaging and distribution of all its products and candidates — so a disruption at one supplier could halt supply. Its biggest revenue threat is regulatory: after the European Commission adopted the CHMP's negative opinion, it faces a substantial risk of losing a significant portion of its Translarna revenue in the EEA, which could prompt other jurisdictions to reassess the drug too. Geopolitics adds a third strand — it contracts with government-owned hospitals and manufacturers in China, exposing it to U.S.-China restrictions, and it carries Russia sanctions and export-control exposure affecting its Russia revenue.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- Translarna EU marketing-authorization loss (CHMP negative opinion)medium
Following the CHMP's negative opinion adopted by the EC, PTC faces a substantial risk of losing a significant portion of its Translarna revenue in the EEA, which may also prompt other jurisdictions to reassess Translarna approvals.
“There is a substantial risk that as a result of the EC's adoption of the CHMP's negative opinion we will lose a significant portion of our ability to generate revenue from sales of Translarna in the EEA.”
SEC filing →As of 2026 - China manufacturers/hospitals + Russia sanctions exposuremedium
PTC contracts with government-owned hospitals and third-party manufacturers in China (amid US-China tension that could restrict supply, manufacturing and commercialization) and faces Russia sanctions/export-control exposure affecting its Russia revenue.
“We also contract with government-owned hospitals and third-party manufacturers located in China, which has recently been involved in political conflict with the United States. This conflict has increased the likelihood of restrictions that could materially and adversely affect our clinical trial sites located in China, our ability to obtain certain supplies, our ability to manufacture certain product candidates”
Sole-source dependency
- single-source raw materials (Translarna, vatiquinone) + third-party CMOs for all APIhigh
PTC relies on single-source raw-material production for Translarna and vatiquinone (and Emflaza), and depends on third-party manufacturers for the API and manufacturing/packaging/distribution of all of its products and candidates.
“For Translarna, we currently rely on a single source for the production of some of our raw materials and we obtain our supply of the drug substance from two third-party manufacturers. For vatiquinone we rely 23 Table of Contents on one source for the production of our raw materials”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
“PTC Therapeutics In 2018, we entered into an exclusive license agreement with PTC Therapeutics to commercialize TEGSEDI and WAYLIVRA in Latin America and certain Caribbean countries.”
Cited →“One of these companies, PTC Therapeutics, Inc. and its affiliates (“PTC”), accounted for approximately 15% of our biologics and drug delivery revenues in 2025. One of our directors is PTC's Chief Executive Officer and President. In May 2019, we entered into a supply agreement with PTC (the “PTC Supply Agreement”) pursuant to which we supply certain products and engage in p”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch